LTGO (Latigo Biotherapeutics) Retained Earnings: $-243.13 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTGO Latigo Biotherapeutics Inc LTGO
8 GF Score
Price $18.56
View Full Analysis

What is Latigo Biotherapeutics Retained Earnings?

Latigo Biotherapeutics LTGO +1.70% 8 Retained Earnings is $-243.13 Mil as of Dec. 2025. GuruFocus rates LTGO with a GF Score™ of 8/100.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Latigo Biotherapeutics's retained earnings for the quarter that ended in Dec. 2025 was $-243.13 Mil.

Latigo Biotherapeutics's quarterly retained earnings increased from . 20 ($0.00 Mil) to Dec. 2024 ($-133.96 Mil) but then declined from Dec. 2024 ($-133.96 Mil) to Dec. 2025 ($-243.13 Mil).

Latigo Biotherapeutics's annual retained earnings increased from . 20 ($0.00 Mil) to Dec. 2024 ($-133.96 Mil) but then declined from Dec. 2024 ($-133.96 Mil) to Dec. 2025 ($-243.13 Mil).


Latigo Biotherapeutics  (NAS:LTGO) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Latigo Biotherapeutics Retained Earnings Historical Data

* Premium members only.

The historical data trend for Latigo Biotherapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Latigo Biotherapeutics Retained Earnings Chart

Latigo Biotherapeutics Annual Data
Trend Dec24 Dec25
Retained Earnings
-133.96 -243.13

Latigo Biotherapeutics Semi-Annual Data
Dec24 Dec25
Retained Earnings -133.96 -243.13
LTGO
8GF Score
Latigo Biotherapeutics Inc LTGO
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Latigo Biotherapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-243.13 Mil mean?
Latigo Biotherapeutics (LTGO) has a Retained Earnings of $-243.13 Mil as of Dec. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on Latigo Biotherapeutics and its competitors.
Is Latigo Biotherapeutics' Retained Earnings too high?
Latigo Biotherapeutics' current Retained Earnings is $-243.13 Mil. Overall, Latigo Biotherapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Latigo Biotherapeutics' Retained Earnings compare to ?
Latigo Biotherapeutics' Retained Earnings of $-243.13 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Latigo Biotherapeutics and its competitors. Latigo Biotherapeutics's current Retained Earnings is $-243.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Latigo Biotherapeutics stock overvalued right now?
Latigo Biotherapeutics (LTGO) has a current Retained Earnings of $-243.13 Mil. The current Retained Earnings is $-243.13 Mil. Latigo Biotherapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Latigo Biotherapeutics (LTGO), the current Retained Earnings is $-243.13 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Latigo Biotherapeutics Business Description

Comparable Companies
Address 1300 Rancho Conejo Boulevard, Suite 305, Thousand Oaks, CA, USA, 91320
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.
8GF Score

Get the complete analysis for LTGO

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.56
Price